Skip to main content

Table 4 Proportion of patients stratified by age group, sex, and treatment group (“concomitant LABA and ICS users”, “switchers”, “non-concomitant LABA and ICS users”, “LABA users without ICS”, “ICS users without LABA”) for the year 2008*

From: Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial

Age group Concomitant LABA and ICS users Switchers Non-concomitant LABA and ICS users LABA users without ICS ICS users without LABA All LABA/ICS treatment categories
  Male Female Male Female Male Female Male Female Male Female Male Female
0-9 4,242 (25.2%) 2,288 (24.2%) 103 (0.6%) 53 (0.6%) 36 (0.2%) 20 (0.2%) 95 (0.6%) 32 (0.3%) 12,376 (73.4%) 7,053 (74.7%) 16,852 (100%) 9,446 (100%)
10-19 10,347 (56.9%) 7,060 (56.1%) 247 (1.4%) 151 (1.2%) 60 (0.3%) 47 (0.4%) 434 (2.4%) 294 (2.3%) 7,095 (39.0%) 5,035 (40.0%) 18,183 (100%) 12,587 (100%)
20-29 6,660 (63.6%) 8,014 (60.8%) 214 (2.0%) 329 (2.5%) 23 (0.2%) 48 (0.4%) 448 (4.3%) 401 (3.0%) 3,123 (29.8%) 4,385 (33.3%) 10,468 (100%) 13,177 (100%)
30-39 7,972 (62.5%) 10,363 (58.7%) 386 (3.0%) 585 (3.3%) 54 (0.4%) 101 (0.6%) 579 (4.5%) 698 (4.0%) 3,758 (29.5%) 5,914 (33.5%) 12,749 (100%) 17,661 (100%)
40-49 11,503 (63.2%) 16,413 (60.4%) 790 (4.3%) 1,129 (4.2%) 95 (0.5%) 179 (0.7%) 904 (5.0%) 1,224 (4.5%) 4,916 (27.0%) 8,222 (30.3%) 18,208 (100%) 27,167 (100%)
50-59 10,310 (62.4%) 15,611 (60.0%) 1,000 (6.1%) 1,494 (5.7%) 112 (0.7%) 209 (0.8%) 1,126 (6.8%) 1,436 (5.5%) 3,962 (24.0%) 7,261 (27.9%) 16,510 (100%) 26,011 (100%)
60-69 12,488 (61.6%) 16,885 (59.7%) 1,659 (8.2%) 1,921 (6.8%) 148 (0.7%) 242 (0.9%) 1,779 (8.8%) 1,794 (6.3%) 4,208 (20.7%) 7,464 (26.4%) 20,282 (100%) 28,306 (100%)
70-79 11,291 (61.7%) 14,340 (60.9%) 1,673 (9.1%) 1,780 (7.6%) 180 (1.0%) 229 (1.0%) 1,868 (10.2%) 1,770 (7.5%) 3,294 (18.0%) 5,445 (23.1%) 18,306 (100%) 23,564 (100%)
80-89 4,071 (64.0%) 6,632 (63.3%) 547 (8.6%) 777 (7.4%) 44 (0.7%) 102 (1.0%) 766 (12.0%) 972 (9.3%) 934 (14.7%) 1,986 (19.0%) 6,362 (100%) 10,469 (100%)
90+ 204 (65.2%) 465 (63.1%) 22 (7.0%) 39 (5.3%) 0 7 (0.9%) 45 (14.4%) 84 (11.4%) 42 (13.4%) 142 (19.3%) 313 (100%) 737 (100%)
Total 79,088 (57.2%) 98,071 (58.0%) 6,641 (4.8%) 8,258 (4.9%) 752 (0.5%) 1,184 (0.7%) 8,044 (5.8%) 8,705 (5.1%) 43,708 (31.6%) 52,907 (31.3%) 138,233 (100%) 169,125 (100%)
  1. *LABA/ICS treatment categories percentage values were calculated for each age group and sex separately.